Altimmune, Inc. (NASDAQ:ALT) Receives $17.17 Consensus PT from Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $17.1667.

Several research firms have recently issued reports on ALT. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. Barclays began coverage on shares of Altimmune in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective on the stock. Citizens Jmp decreased their price objective on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Monday, October 20th. Finally, Citigroup reiterated a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th.

Altimmune Stock Performance

NASDAQ:ALT opened at $4.53 on Wednesday. The firm has a market capitalization of $511.12 million, a PE ratio of -4.23 and a beta of 0.09. The stock’s fifty day moving average is $4.62 and its 200 day moving average is $4.21. Altimmune has a fifty-two week low of $2.90 and a fifty-two week high of $7.73. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18.

Insiders Place Their Bets

In other Altimmune news, Director Jerome Benedict Durso bought 12,500 shares of Altimmune stock in a transaction on Monday, December 22nd. The shares were acquired at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the purchase, the director directly owned 12,500 shares in the company, valued at approximately $51,625. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director John Gill bought 12,500 shares of the stock in a transaction dated Tuesday, December 23rd. The shares were bought at an average cost of $4.10 per share, with a total value of $51,250.00. Following the completion of the purchase, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,250. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders acquired 30,527 shares of company stock worth $125,278. Insiders own 4.40% of the company’s stock.

Institutional Trading of Altimmune

Institutional investors and hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. lifted its stake in Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock valued at $247,000 after purchasing an additional 2,241 shares in the last quarter. Concurrent Investment Advisors LLC raised its holdings in shares of Altimmune by 10.4% in the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after purchasing an additional 2,500 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock worth $108,000 after purchasing an additional 2,748 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of Altimmune by 4.0% during the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock valued at $289,000 after purchasing an additional 3,047 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.